Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a significant decrease in short interest in September. As of September 15th, there was short interest totaling 38,427 shares, a decrease of 88.7% from the August 31st total of 340,186 shares. Approximately 4.4% of the shares of the stock are short sold. Based on an average daily volume of 136,492 shares, the days-to-cover ratio is currently 0.3 days.
Wall Street Analysts Forecast Growth
VBIO has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Valion Bio, Inc. Common Stock to a “hold” rating in a research report on Saturday, September 5th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock has a consensus rating of “Sell”.
Check Out Our Latest Report on Valion Bio, Inc. Common Stock
Valion Bio, Inc. Common Stock Stock Performance
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc was incorporated in 2016 and is headquartered in Hayward, California.
See Also
- Five stocks we like better than Valion Bio, Inc. Common Stock
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
